Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 70/100

Indivior Announces Q2 2024 Financial Results Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor...

Key Takeaway: Indivior PLC has announced its financial results for the second quarter of 2024. The company aims to improve treatment access for substance use disorders and is developing a range of medicines in this field. The CEO, Mark Crossley, will host a live webcast to discuss the results and provide further insights. Indivior's commitment to addressing chronic conditions and expanding its treatment portfolio highlights its ongoing efforts to combat substance use disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior reported strong financial results for Q2 2024.
  • The company is dedicated to transforming substance use disorders into recognized chronic diseases.
  • Indivior has a diverse pipeline of product candidates targeting various substance use disorders.

Full Press Release Details

SLOUGH, UK and RICHMOND, Va. , July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024 . The earnings release, investor presentation and webcast are available at www.indivior.com .
There will be a live webcast presentation at 13:00 BST ( 8:00 am ET ) hosted by Mark Crossley , CEO. The details are below.
Webcast link: https://edge.media-server.com/mmc/p/jpgy4cd9 Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BIdf08b662a5f24248bf5f8677f59ef713
(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA , Indivior employs approximately 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .

21 %

Frequently Asked Questions

What are Indivior's recent financial results?

Indivior PLC announced its financial results for the period ending June 30, 2024.

When is Indivior's live webcast presentation?

The live webcast presentation is scheduled for July 25, 2024, at 13:00 BST.

How can I access Indivior's investor presentation?

The investor presentation can be accessed via Indivior's website at www.indivior.com.

What is the focus of Indivior's products?

Indivior develops medicines for treating substance use disorders and mental illnesses.

In how many countries are Indivior's products available?

Indivior's products are available in 37 countries worldwide.

Last updated: Jul 25, 2024